Roman Yelensky, VP of Clinical Applications at 10x Genomics, outlined the company’s strategic role in advancing spatial and single-cell technologies within oncology, positioning them as critical tools for understanding tumour biology at unprecedented resolution.

While currently designated for research use only, 10x Genomics’ platforms enable detailed interrogation of tumour, immune, and stromal cell interactions, providing insights into cellular heterogeneity and the tumour microenvironment. A key differentiator is the robustness of these technologies and their compatibility with routine clinical specimens, including formalin-fixed, paraffin-embedded (FFPE) tissues—an essential step toward translational and future diagnostic applications.

Yelensky identified the primary bottleneck to clinical adoption as the lack of large-scale clinical evidence, particularly datasets linking spatial and single-cell readouts to patient outcomes. Addressing this gap is central to 10x Genomics’ strategy, with significant investment in clinical data generation to validate predictive biomarkers and therapeutic response signatures.

Emerging studies already demonstrate the value of spatial context in oncology, where tumour microenvironment architecture can explain variability in drug response beyond target expression alone. This reinforces the importance of integrating multi-dimensional data into patient stratification frameworks.

Collaboration plays a pivotal role in this ecosystem. Partnerships with leading institutions such as Dana-Farber Cancer Institute and Brigham and Women’s Hospital are enabling translational research across oncology and autoimmune diseases, combining clinical expertise with advanced genomic technologies to accelerate discovery.

Looking ahead, 10x Genomics is expanding its footprint into clinical implementation, including the development of a CLIA-certified laboratory to support the deployment of clinically actionable assays. This move reflects a broader strategic shift—from enabling discovery to actively facilitating the translation of high-resolution genomic insights into real-world clinical applications.

Yelensky emphasised that as technical barriers such as cost, throughput, and sample compatibility continue to diminish, the field is approaching an inflection point—where integrated spatial and single-cell analyses can move from research settings into routine clinical decision-making, shaping the future of precision oncology.